vic3308

2023-07-12

¸´ÐÇÒ½Ò©Á¢ÒìÒ©ÑÎËáÌæÄÉÅÁŵƬ?»ñÉÏÊÐÉêÇëÊÜÀí ÓÃÓÚÖÎÁÆÂýÐÔÉöÔಡѪ͸»¼Õ߸ßÁ×Ѫ֢

£¨2023Äê7ÔÂ12ÈÕ£¬£¬ £¬ £¬£¬ÖйúÉϺ££©7ÔÂ12ÈÕ£¬£¬ £¬ £¬£¬ÉϺ£¸´ÐÇÒ½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°¸´ÐÇÒ½Ò©¡±£¬£¬ £¬ £¬£¬¹ÉƱ´úÂ룺600196.SH£»£»£»£» £»£»£»£»02196.HK£©Ðû²¼£¬£¬ £¬ £¬£¬¿Ø¹É×Ó¹«Ë¾ÉϺ£¸´ÐÇÒ½Ò©¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾£¨¡°¸´ÐÇÒ½Ò©¹¤Òµ¡±£©»ñÔÊÐíÁ¢ÒìÒ©TenapanorƬ£¨ÑÎËáÌæÄÉÅÁŵƬ£¬£¬ £¬ £¬£¬¡°¸ÃÐÂÒ©¡±£©ÓÃÓÚ¿ØÖÆÕýÔÚ½ÓÊÜѪҺ͸ÎöÖÎÁƵÄÂýÐÔÉöÔಡ£¡£ ¡£¡£¡£¡£¨CKD£©³ÉÈË»¼ÕߵĸßÁ×Ѫ֢µÄÒ©Æ·×¢²áÉêÇëÓÚ¿ËÈÕ»ñ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨¡°¹ú¼ÒÒ©¼à¾Ö¡±£©ÉóÆÀÊÜÀí¡£¡£ ¡£¡£¡£¡£

TenapanorƬÊǸ´ÐÇÒ½Ò©´ÓArdelyxÔÊÐíÒýÈëµÄÒ»¿îFirst-in-class¿Ú·þ³¦µÀÄÆ/Çâ½»Á÷Ìå3£¨NHE3£©ÒÖÖÆ¼Á£¬£¬ £¬ £¬£¬2017Äê12Ô£¬£¬ £¬ £¬£¬¸´ÐÇÒ½Ò©¹¤Òµ»ñµÃÁËTenapanorƬÔÚÖк£Äڵء¢Ïã¸Û¼°°ÄÃÅÌØÊâÐÐÕþÇøµÄ¶À¼ÒÁÙ´²¿ª·¢ºÍÉÌÒµ»¯µÈȨÁ¦¡£¡£ ¡£¡£¡£¡£TenapanorƬΪ»¯Ñ§Ò©Æ·£¬£¬ £¬ £¬£¬¸ÃÐÂÒ©ÓÃÓÚ±ãÃØÐͳ¦Ò×¼¤×ÛºÏÖ¢ÖÎÁÆÒÑÓÚ2019Äê9Ô»ñÃÀ¹úFDA£¨¼´ÃÀ¹úʳÎïºÍÒ©Æ·¼àÊÓÖÎÀí¾Ö£©ÉÏÊÐÅú×¼£¬£¬ £¬ £¬£¬²¢ÒÑÓÚ2023Äê3ÔÂÔÚÖйúÏã¸ÛÌØÊâÐÐÕþÇøµÝ½»ÉÏÊÐÉêÇ룻£»£»£» £»£»£»£»×èÖ¹ÏÖÔÚ£¬£¬ £¬ £¬£¬¸Ã˳Ӧ֢ÓÚÖйú¾³ÄÚ£¨²»°üÀ¨¸Û°Ą̈µØÇø£©ÒÑÍê³ÉIÆÚÁÙ´²ÊÔÑé½×¶Î¡£¡£ ¡£¡£¡£¡£TenapanorƬÓÃÓÚ³ÉÈËÂýÐÔÉöÔಡ£¡£ ¡£¡£¡£¡£¨CKD£©Í¸Îö»¼ÕßµÄѪÇåÁ׿ØÖƵÄÉÏÊÐÉêÇëÕýÔÚ½ÓÊÜÃÀ¹úFDAµÄ×¢²áÉó²é¡£¡£ ¡£¡£¡£¡£

TenapanorƬ¿ÉÒÔïÔÌ­³¦µÀÄÆÀë×ÓÎüÊÕ£¬£¬ £¬ £¬£¬ÔöÌí³¦Ç»ÄÚË®·Ö£¬£¬ £¬ £¬£¬Ôö½ø³¦µÀÈ䶯ºÍÕý³£ÅűãµÄƵÂÊ¡£¡£ ¡£¡£¡£¡£¶àÏîÃÀ¹úºÍÈÕ±¾µÄ¢ò¡¢¢óÆÚÑо¿Åú×¢TenapanorƬ¿ÉÏÔÖø½µµÍѪҺ͸Îö»¼ÕßÉý¸ßµÄѪÁ×ˮƽ£¬£¬ £¬ £¬£¬ÔÚ³¤´ï52ÖܵÄÓÃÒ©ÊÔÑéÖÐÒ²ÏÔʾËüµÄÖÎÁÆ¿ÉÄÍÊÜÐÔ£¬£¬ £¬ £¬£¬ÔÚÖйúÖÕÄ©ÆÚÉöÔಡ£¡£ ¡£¡£¡£¡£¨ESRD£©ÑªÍ¸°é¸ßÁ×Ѫ֢»¼ÕßÖпªÕ¹µÄTenapanorƬ¢óÆÚÑо¿Ð§¹ûÓëÒѽÒÏþÑо¿Ð§¹ûÒ»Ö£¬£¬ £¬ £¬£¬Î´·¢Ã÷еÄÇå¾²ÐÔÐźÅ1.2.3.¡£¡£ ¡£¡£¡£¡£Ñо¿Ð§¹ûÖ§³ÖTenapanorƬÓÃÓÚÖйúESRDѪ͸°é¸ßÁ×Ѫ֢»¼ÕߵĽµÁ×ÖÎÁÆ¡£¡£ ¡£¡£¡£¡£2023Äê6ÔÂ16ÈÕµÚ68½ìÈÕ±¾Í¸Îöҽѧ»áÄêÉÏ£¬£¬ £¬ £¬£¬¸´ÐÇÒ½Ò©¿ÚÍ·»ã±¨ÁËTenapanorƬÖйúIIIÆÚÑо¿Ð§¹û¡£¡£ ¡£¡£¡£¡£

¡ª¡ª¡ª¡ª¡ª¡ª¡ª¡ª

²Î¿¼ÎÄÏ×£º
1.Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30: 641¨C52.
2.Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep 2021; 7: 177¨C88.
3.Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2: 1600¨C10.

¹ØÓÚ¸´ÐÇÒ½Ò©


ÉϺ£¸´ÐÇÒ½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°¸´ÐÇÒ½Ò©¡±£¬£¬ £¬ £¬£¬¹ÉƱ´úÂ룺600196.SH£¬£¬ £¬ £¬£¬02196.HK£©½¨ÉèÓÚ1994Ä꣬£¬ £¬ £¬£¬ÊÇÒ»¼ÒÖ²¸ùÖйú¡¢Á¢ÒìÇý¶¯µÄÈ«Çò»¯Ò½Ò©¿µ½¡¹¤Òµ¼¯ÍÅ£¬£¬ £¬ £¬£¬Ö±½ÓÔËÓªµÄÓªÒµ°üÀ¨ÖÆÒ©¡¢Ò½ÁÆÆ÷еÓëҽѧÕï¶Ï¡¢Ò½ÁÆ¿µ½¡Ð§ÀÍ£¬£¬ £¬ £¬£¬²¢Í¨¹ý²Î¹É¹úÒ©¿Ø¹ÉÁýÕÖµ½Ò½Ò©ÉÌÒµÁìÓò¡£¡£ ¡£¡£¡£¡£


¸´ÐÇÒ½Ò©ÒÔ»¼ÕßΪÖÐÐÄ¡¢ÁÙ´²ÐèÇóΪµ¼Ïò£¬£¬ £¬ £¬£¬Í¨¹ý×ÔÖ÷Ñз¢¡¢ÏàÖú¿ª·¢¡¢ÔÊÐíÒý½ø¡¢Éî¶È·õ»¯µÈ¶àÔª»¯¡¢¶àÌõÀíµÄÏàÖúģʽ£¬£¬ £¬ £¬£¬Ò»Á¬¸»ºñÁ¢Òì²úÆ·¹ÜÏߣ¬£¬ £¬ £¬£¬ÌáÉýFIC£¨First-in-class£¬£¬ £¬ £¬£¬¼´Í¬ÀàÊ×´´£©ÓëBIC£¨Best-in-class£¬£¬ £¬ £¬£¬¼´Í¬Àà×î¼Ñ£©ÐÂÒ©µÄÑо¿ÓëÁÙ´²¿ª·¢ÄÜÁ¦£¬£¬ £¬ £¬£¬¼ÓËÙÁ¢ÒìÊÖÒպͲúÆ·µÄÑз¢ºÍת»¯Â䵨¡£¡£ ¡£¡£¡£¡£


ÔÚ¡°4IN¡±£¨Á¢ÒìInnovation¡¢¹ú¼Ê»¯ Internationalization¡¢ÖÇÄÜ»¯ Intelligentization¡¢ÕûºÏ Integration£©µÄÕ½ÂÔÖ¸µ¼Ï£¬£¬ £¬ £¬£¬¸´ÐÇÒ½Ò©³Ð¼Ì¡°Á¢ÒìתÐÍ¡¢ÕûºÏÔËÓª¡¢ÎȽ¡ÔöÌí¡±µÄÉú³¤Ä£Ê½ÒÔ¼°Îª¹É¶«´´Á¢¼ÛÖµµÄÐÅÐÄ£¬£¬ £¬ £¬£¬Ò»Ö±ÔöÇ¿×ÔÖ÷Ñз¢ÓëÍⲿÏàÖú£¬£¬ £¬ £¬£¬¸»ºñ²úÆ·¹ÜÏߣ¬£¬ £¬ £¬£¬Ç¿»¯È«Çò»¯½á¹¹£¬£¬ £¬ £¬£¬ÌáÉýÔËӪЧÂÊ£¬£¬ £¬ £¬£¬Í¬Ê±£¬£¬ £¬ £¬£¬Æð¾¢ÍƽøÒ½ÁÆ¿µ½¡¹¤ÒµÏßÉÏÏßϽṹ£¬£¬ £¬ £¬£¬ÖÂÁ¦ÓÚ³ÉΪȫÇòÒ½ÁÆ¿µ½¡Êг¡µÄÒ»Á÷ÆóÒµ¡£¡£ ¡£¡£¡£¡£


Ïàʶ¹«Ë¾¸ü¶à×ÊѶ¿ÉµÇ¼¹ÙÍø£ºwww.fosunpharma.com


ǰհÐÔÉùÃ÷£º
±¾ÐÂΟå°üÀ¨Ç°Õ°ÐÔÉùÃ÷¡£¡£ ¡£¡£¡£¡£³ý±¾ÐÂΟåËùÔØµÄÀúÊ·ÊÂʵ³ÂÊöÍ⣬£¬ £¬ £¬£¬ËùÓаüÀ¨µ«²»ÏÞÓÚ±¾¹«Ë¾ÉÌÒµÕ½ÂÔµÄÌÖÂÛ£¬£¬ £¬ £¬£¬¹ØÓÚδÀ´ÔËÓª¡¢ÀûÈóÂÊ¡¢Ó¯ÀûÄÜÁ¦¡¢Á÷¶¯ÐÔºÍ×ÊÔ´×ÊÔ´¡¢±¾¹«Ë¾ÐÐҵδÀ´Éú³¤ºÍÖ÷ÒªÊг¡×ÜÌå¾­¼ÃδÀ´Éú³¤µÄÔ¤ÆÚµÄÌÖÂÛ£¬£¬ £¬ £¬£¬ÒÔ¼°ÈκÎÔÚ´Ë֮ǰ¡¢Ö®ºó»ò°üÀ¨ÖîÈç¡°ÆÚÍû¡±¡¢¡°×·Ç󡱡¢¡°ÐÅÍС±¡¢¡°ÍýÏ롱¡¢¡°ÍýÏ롱¡¢¡°Ô¤¼Æ¡±¡¢¡°ÏîÄ¿¡±¡¢¡°Ô¤ÆÚ¡±¡¢¡°¿ÉÄÜ¡±¼°¡°½«Òª¡±µÈÓ빫˾»òÆäÖÎÀí²ãÓйصÄÀàËÆ´ÊÓï»ò³ÂÊö£¬£¬ £¬ £¬£¬¾ùÖ¼ÔÚÈ·¶¨Ç°Õ°ÐÔ³ÂÊö¡£¡£ ¡£¡£¡£¡£ÕâЩ³ÂÊöÊÜijЩÒÑÖªºÍδ֪µÄΣº¦¡¢²»È·¶¨ÐԺͼÙÉèµÄÓ°Ïì¿ÉÄܵ¼Ö¹«Ë¾µÄÏÖʵЧ¹û¡¢Òµ¼¨»ò³É¼¨ÓëÕâЩǰհÐÔÉùÃ÷Ëù±í´ï»òÌåÏÖµÄÈκÎδÀ´Ð§¹û¡¢Òµ¼¨»ò³É¼¨±£´æÖØ´ó²î±ð¡£¡£ ¡£¡£¡£¡£Òò´Ë£¬£¬ £¬ £¬£¬Äú²»Ó¦Ì«¹ýÒÀÀµÈκÎǰհÐÔµÄ×ÊÁÏ¡£¡£ ¡£¡£¡£¡£Æ¾Ö¤ÊÊÓõÄÖ´·¨¡¢¹æÔòºÍÌõÀýµÄÒªÇ󣬣¬ £¬ £¬£¬ÎÞÂÛÊÇÓÉÓÚеÄÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÉú³¤»òÆäËûÔµ¹ÊÔ­ÓÉ£¬£¬ £¬ £¬£¬±¾¹«Ë¾Ã»ÓÐÒ²²»¼ç¸ºÈκθüлòÒÔÆäËû·½·¨Ð޸ı¾ÐÂΟåÖеÄǰհÐÔÉùÃ÷µÄÒåÎñ¡£¡£ ¡£¡£¡£¡£ÔÚ±¾ÐÂΟåÖУ¬£¬ £¬ £¬£¬Óйع«Ë¾ÒâÏòµÄÉùÃ÷»ò²Î¿¼ÎÄÏ××Ô±¾ÐÂΟåÐû²¼Ö®ÈÕÆðÉúЧ¡£¡£ ¡£¡£¡£¡£ÈκδËÀàÒâͼ¶¼¿ÉÄÜËæ×ÅδÀ´µÄÉú³¤¶ø¸Ä±ä¡£¡£ ¡£¡£¡£¡£±¾ÐÂΟåËùÔØµÄËùÓÐǰհÐÔÉùÃ÷¾ù²ÎÕÕÉÏÊöÉêâÁÐÔÉùÃ÷¼ÓÒÔÏÞÖÆ¡£¡£ ¡£¡£¡£¡£

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿